Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Pfizer RSV prefusion F vaccine in older adults
NL-OMON52252Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing RSVpreF vaccine with Placebo (2 arms). Primary endpoints: Vaccine efficacy against first-episode LRTI-RSV with at least 2 signs or symptoms in first RSV season, Vaccine efficacy against first-episode LRTI-RSV with at least 3 signs or symptoms in first RSV season and 5 more. Started Oct 2021; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON52252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52252.